Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: An analysis of the cholecystokinin system

Archives of Neurology

Volumn 61, Issue 8, 2004, Pages 1280-1284

  Goldman, Jennifer G ^a   Goetz, Christopher G ^a   Berry Kravis, Elizabeth ^a   Leurgans, Sue ^a   Zhou, Lili ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; GENE PRODUCT; LEVODOPA;

AGED; ALLELISM; ARTICLE; CCKAR GENE; CCKBR GENE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA ISOLATION; DOPAMINERGIC SYSTEM; ETHNOLOGY; FEMALE; GENE; GENE FREQUENCY; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALLELES; CASE-CONTROL STUDIES; CHOLECYSTOKININ; DOPAMINE AGENTS; FEMALE; GENE FREQUENCY; HALLUCINATIONS; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, GENETIC; RECEPTORS, CHOLECYSTOKININ;

EID: 4043079333     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.61.8.1280     Document Type: Article

References (26)

1. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology. 1993;43:2227-2229.
2. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology. 1995;45:669-671.
3. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology, and risk factors. Brain. 2000;123:733-745.
4. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neurol. 1996;53:1265-1268.
5. van Veelen NM, Kahn RS.,Dopamine, serotonin, and schizophrenia. Adv Neurol. 1999;80:425-429.
6. Goetz CG, Burke PF, Leurgans S, et al. Genetic variation analysis in Parkinson disease patients with and without hallucinations. Arch Neurol. 2001;58:209-213.
7. Wei J, Hemmings GP. The CCK-A receptor gene possibly associated with auditory hallucinations in schizophrenia. Eur Psychiatry. 1999;14:67-70.
8. Wang J, Mei Y, Liu Z. Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B gene polymorphisms in Parkinson's disease. Pharmacogenetics. 2003;13:365-369.
9. Crawley JN. Cholecystokinin-dopamine interactions. Trends Pharmacol Sci. 1991;12:232-236.
10. Fujii C, Harada S, Ohkoshi N, et al. Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson's disease. Clin Genet. 1999;56:394-399.
11. Sweet RA, Nimgaonkar VL, Kamboh MI, et al. Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease. Arch Neurol. 1998;55:1335-1340.
12. Zhang XY, Zhou DF, Zhang PY, Wei J. The CCK-A receptor gene possibly associated with positive symptoms of schizophrenia. Mol Psychiatry. 2000;5:239-240.
13. Ishiguro H, Saito T, Shibuya H, et al. No association between C-45T polymorphism in the Sp1 binding site of the promoter region of the cholecystokinin gene and alcoholism. Psychiatry Res. 1999;85:209-213.
14. B receptor polymorphisms with alcohol dependence. Psychiatry Res. 2001; 102:1-7.
15. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990, Neurology. 1999;52:1214-1220.
16. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson's disease. Am J Epidemiol. 2003;157:1015-1022.
17. Fernandez HH, Lapane KL, Ott BR, et al. Gender differences in the frequency and treatment of behavior problems in Parkinson's disease. Mov Disord. 2000;15:490-496.
18. Harada S, Okubo T, Tsutsumi M, Takase S, Muramatsu T. A new genetic variant in the Sp1 binding cis-element of cholecystokinin gene promoter region and relationship to alcoholism. Alcohol Clin Exp Res. 1998;22(suppl):93S-96S.
19. Goetz CG, Leurgans S, Pappert EJ, et al. Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology. 2001;57:2078-2082.
20. Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999;67:492-496.
21. Studler JM, Javoy-Agid F, Cesselin F, et al. CCK-8 immunoreactivity distribution in human brain. Brain Res. 1982;243:176-179.
22. Hansen TVO. Cholecystokinin gene transcription: promoter elements, transcription factors and signaling pathways. Peptides. 2001;22:1201-1211.
23. Tachikawa H, Harada S, Kawanishi Y, et al. Novel polymorphisms of the human cholecystokinin A receptor gene. Am J Med Genet. 2000;96:141-145.
24. Okubo T, Harada S. Polymorphisms of the CCK, CCKAR, and CCKBR genes: an association with alcoholism study. J Stud Alcohol. 2001;62:413-421.
25. Wang Z, Valdes J, Noyes R, et al. Possible association of a cholecystokinin promoter polymorphism (CCK-36CT) with panic disorder. Am J Med Genet. 1998;81:228-234.
26. Bowen T, Norton N, Jacobsen NJO, et al. Linked polymorphisms upstream of exon 1 and exon 2 of the human cholecystokinin gene are not associated with schizophrenia or bipolar disorder. Mol Psychiatry. 1998;3:67-71.